

Anti CCP GENLISA® ELISA

REF : KBD281

Ver 2.7

IVD

Enzyme Immunoassay for the Quantitative Determination of Anti
CCP in human serum and plasma

IVD	For In-vitro Diagnostic Use	REF	Catalog Number
	Store At	LOT	Batch Code
	Manufactured By		Biological Risk
	Expiry Date		Consult Operating Instructions

For In-vitro Diagnostic Use only. Purchase does not include or carry the right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of KRISHGEN Pudgala LLP is strictly prohibited.

REF KBD281 **96 tests**

Krishgen Pudgala LLP Unit Nos#318/319, Shah & Nahar, Off Dr E Moses Road, Worli, Mumbai 400018. India.
Tel: +91-22-49198700 | email: sales@krishgenpudgala.com

Introduction:

The CCP (cyclic citrullinated peptide) antibody is an autoantibody against citrullinated proteins (ACPA). They are present in the majority of patients with rheumatoid arthritis. Rheumatoid arthritis (RA) is the most common inflammatory autoimmune disorder, causing progressive joint destruction as a result of chronic synovitis. Clinically, cyclic citrullinated peptides (CCP) are frequently used to detect these antibodies in patient serum or plasma (then referred to as anti-citrullinated peptide antibodies).

Intended Use:

The Anti CCP GENLISA® ELISA is intended for the quantitative determination of IgG class of autoantibodies specific to the Anti CCP in human serum and plasma.

Principle:

The Anti CCP GENLISA® ELISA is an indirect enzyme linked immunosorbent assay for quantitative determination of IgG antibody present in the human serum and plasma. The Microtiter wells are pre-coated with Streptavidin. Biotinylated CCP Peptide and serum samples and Controls are pipetted into Streptavidin-coated wells. After incubation and washing Anti-Human IgG:HRP Conjugate is added. After washing microwells in order to remove any non-specific binding, the substrate solution is added to microwells and color develops proportionally to the amount of the Anti CCP present in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Materials Provided:

1. Streptavidin coated Microtiter Plate (96 wells) - 1 no
2. CCP Standards (1.0 ml/vial) - 0, 10, 25, 75, 125, 250 RU/ml
3. Sample diluent – 2 X 50 ml
4. Low Control Serum – 1 ml
5. High Control Serum – 1 ml
6. Biotinylated CCP Peptide – 3 ml
7. Anti-Human IgG:HRP Conjugate (concentrated) (20X) - 1 ml
8. HRP Conjugate Diluent - 12 ml
9. (10X) Wash Buffer – 2 X 50 ml
10. TMB Substrate - 12 ml
11. Stop Solution - 12 ml
12. Instruction Manual

Materials to be provided by the End-User:

1. Microtiter Plate Reader able to measure absorbance at 450 nm.
2. Adjustable pipettes and multichannel pipette to measure volumes ranging from 10 ul to 1000 ul.
3. Deionized (DI) water.
4. Wash bottle or automated microplate washer.
5. Graph paper or software for data analysis.
6. Timer.
7. Absorbent Paper.

Handling/Storage:

1. Store main kit components at recommended storage temperature indicated on the component label.
2. Before using, bring all components to room temperature (18-25°C). Upon assay completion return all components to appropriate storage conditions.
3. The Substrate is light-sensitive and should be protected from direct sunlight or UV sources.

Health Hazard Warnings:

1. Reagents that contain preservatives may be harmful if ingested, inhaled or absorbed through the skin. Refer to the MSDS online for details.
2. To reduce the likelihood of blood-borne transmission of infectious agents, handle all serum and/or plasma in accordance with NCCLS regulations.

**Specimen Collection and Handling:**

Serum- Coagulate at room temperature for 10-20 minutes; centrifuge for 20-min at 2000-3000 rpm. Remove the supernatant. If precipitation appears, re-centrifuge.

Plasma- Use EDTA or citrate plasma as an anticoagulant, mix for 10-20 minutes; centrifuge for 15-min at 2000-3000 rpm. Remove the supernatant carefully. If precipitation appears, re-centrifuge.

Sample Dilution:

To make 1:101 Dilutions, dilute 10 ul Sample + 1000ul Sample Diluent. Mix well.

Reagent Preparation:

1. Allow all components to reach RT (Room Temperature) prior to use in the assay.
2. **Anti-Human IgG:HRP Conjugate working solution** – To prepare the required amount of conjugate, dilute the concentrated conjugate with the HRP conjugate Diluent in a ratio of 1:20. Mix it well. For eg. To prepare 1 ml of ready to use Conjugate working solution, mix 50ul of concentrated **Anti-Human IgG:HRP Conjugate** with 950ul of **HRP conjugate diluent**.
3. **Wash Buffer (1X) Dilution:** To make Wash Buffer (1X), add 50ml of Wash Buffer (10X) to 450ml of DI water. This is the working solution.

Test Procedure:

1. All reagents should be allowed to reach room temperature before use.
2. Add **25 ul** of **Biotinylated CCP Peptide** in appropriate wells.
3. Add **100 ul Standard, High Control, Low Control and Diluted Sample** in appropriate wells in duplicate.
4. Cover the plate and incubate for 60 minutes at room temperature (22-28°C).
5. Aspirate and wash plate 5 times with **(1X) Wash Buffer** and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe off any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step. All the washes should be performed similarly.
6. Add **100 ul** of **Anti-Human IgG:HRP Conjugate working solution** to each well.
7. Cover the plate and incubate for 30 minutes at room temperature (22-28°C).
8. Repeat the Wash Step as mentioned in step 5.
9. Add **100 ul** of **TMB Substrate** into each well.
10. Incubate at room temperature for 15 minutes in dark.
11. Add **100 ul** of **Stop Solution**. Read result with an ELISA reader at 450 nm.

Interpretation of Results:

Determine the Mean Absorbance for each set of duplicate or triplicate Standards and Samples. Using graph paper, plot the average value (absorbance 450 nm) of each standard on the Y-axis versus the corresponding concentration of the standards on the X-axis. Draw the best fit curve through the standard points. To determine

the unknown Anti CCP concentrations, find the unknown's Mean Absorbance value on the Y-axis and draw a horizontal line to the standard curve. At the point of intersection, draw a vertical line to the X-axis and read the Anti CCP Concentration. If samples were diluted, multiply by the appropriate dilution factor.

Software which is able to generate a cubic spline curve-fit, 4-PL or a polynomial curve (2nd order) is best recommended for automated results.

Note:

- If the sample reads more than 100 U/ml, then dilute with Standard 0. The obtained result should be multiplied by the dilution factor.

Validity of the controls:

The test is valid if the below condition is met:

Low Control Serum: 6 – 15 RU/ml

High Control Serum: 75 – 165 RU/ml

Expected Values:

It is important for each laboratory to establish the normal range limits. The following reference range from healthy persons should be considered as a 215 guideline only. Anti-CCP IgG was measured in healthy persons. The mean value obtained was 3.38 RU/ml. The cut-off has been calculated based on mean divided by 3SD as 15RU/ml.

Performance Characteristics:

1. Comparative Study:

The Anti-CCP IgG GENLISA® kit was compared with the commercially available Anti-CCP IgG Elisa kit.

2. Minimum Detection Limit:

The LOD of Anti-CCP IgG by this assay is estimated to be **0.6 RU/ml**.

3. Precision:

Intra-Assay precision:

Within assay variability is shown below:

No.	No. of Tests Performed	Means RU/ml	SD RU/ml	CV%
1	20	2.6	0.19	7.3
2	20	50.3	4.5	8.9
3	20	169	8.2	4.9

Inter-Assay precision:

Between assays variability is shown below:

No.	No. of Tests Performed	Means RU/ml	SD RU/ml	CV%
1	20	2.5	0.26	10.4
2	20	47.2	5.3	11.2
3	20	167	9.0	5.4

*Each test has been run in duplicate

4. Interference:

To determine the interferences with the kit, the following amounts of hemoglobin, triglyceride and bilirubin were added to three specimens and the neutralizing antibody concentration was measured before and after the involvement of the substances mentioned above the results is shown in the table below:

Interferent Analyte	The Concentration of the interferent analyte	The value of the specimen before adding the interferent (RU/ml)	The value of the specimen after adding the interferent (RU/ml)	The Change of the results (%)
Hemoglobin	1 mg/ml	3.3	3.3	-1.1
		19.6	19.9	1.5
		163	162	-1.0
Triglyceride	3000 mg/dl	3.3	3.4	1.1
		19.6	18.9	-3.5
		163	164	0.67
Bilirubin	20 mg/dl	3.36	3.3	0.29
		19.6	20.1	2.5
		163	162	-1.0

5. Test Linearity:

To verify test linearity, three different serum samples with known Anti-CCP IgG concentrations were diluted sequentially by sample diluent. Then the Sera were tested by the ELISA. The results and serum recovery were determined considering the dilution factor.

No.	Anti-CCP IgG (RU/ml) Undiluted specimen	Recovery (%)			
		1:2	1:4	1:8	1:16
1	248	106	86.9	114	96.2
2	202	103	93.7	91.7	81.7
3	148	96.6	93.6	87.4	91.1

6. Test Recovery:

Certain amounts of Anti-CCP IgG were added to 3 different sera with known concentrations of Anti-CCP IgG and then their recovery was determined. The results are shown below:

No.	Anti-CCP IgG level RU/ml	Anti-CCP IgG added RU/ml	Exp. RU/ml	Obs. RU/ml	Rec. (%)
1	201	115	158	143	90.5
2	74.6	115	95.2	104	109
3	8.4	115	62.1	61.5	99.0
1	201	50.6	125	114	91.2
2	74.6	50.6	62.6	59.1	94.4
3	8.4	50.6	29.5	26.8	90.8
1	201	188	194	207	106.7
2	74.6	188	131	120	91.6
3	8.4	188	98.2	91.6	93.3

Safety Precautions:

- **This kit is For In-vitro Diagnostic Use only.** Follow the working instructions carefully.
- The expiration dates stated on the kit are to be observed. The same relates to the stability stated for reagents.
- Do not use or mix reagents from different lots.
- Do not use reagents from other manufacturers.
- Avoid time shift during pipetting of reagents.
- All reagents should be kept in the original shipping container.
- Some of the reagents contain small amount of sodium azide (< 0.1 % w/w) as preservative. They must not be swallowed or allowed to come into contact with skin or mucosa.
- Source materials maybe derived from human body fluids or organs used in the preparation of this kit were tested and found negative for HBsAg and HIV as well as for HCV antibodies. However, no known test guarantees the absence of such viral agents. Therefore, handle all components and all patient samples as if potentially hazardous.
- Since the kit contains potentially hazardous materials, the following precautions should be observed.
 - Do not smoke, eat or drink while handling kit material.
 - Always use protective gloves.
 - Never pipette material by mouth.
 - Wipe up spills promptly, washing the affected surface thoroughly with a decontaminant.
- In any case GLP should be applied with all general and individual regulations to the use of this kit.



LIMITED WARRANTY

Krishgen Pudgala LLP does not warrant against damages or defects arising in shipping or handling, or out of accident or improper or abnormal use of the product; against defects in products or components not manufactured by Krishgen Pudgala LLP, or against damages resulting from such non-Krishgen Pudgala LLP made products or components. Krishgen Pudgala LLP passes on to customer the warranty it received (if any) from the maker thereof of such non-Krishgen made products or components. This warranty also does not apply to product to which changes or modifications have been made or attempted by persons other than pursuant to written authorization by Krishgen Pudgala LLP.

THIS WARRANTY IS EXCLUSIVE. The sole and exclusive obligation of Krishgen Pudgala LLP shall be to repair or replace the defective product in the manner and for the period provided above. Krishgen Pudgala LLP shall not have any other obligation with respect to the products or any part thereof, whether based on contract, tort, strict liability or otherwise. Under no circumstances, whether based on this Limited Warranty or otherwise, shall Krishgen Pudgala LLP be liable for incidental, special, or consequential damages.

This Limited Warranty states the entire obligation of Krishgen Pudgala LLP with respect to the product. If any part of this Limited Warranty is determined to be void or illegal, the remainder shall remain in full force and effect.

Krishgen Pudgala LLP, 2026.

THANK YOU FOR USING A KRISHGEN PRODUCT!



Krishgen Pudgala LLP

Unit No.1/2, Om Sainath Commercial Complex,
Off Mankoli-Anjur Phata Road. Village Dapode, Bhiwandi 421302.



KinesisDx, Lyoner Strasse 14, Frankfurt, Germany

Regulatory Status:

CE Marked	Europe
FDA registered	USA
CDSCO registered	India

SCHEMATIC ASSAY PROCEDURE

1	All reagents should be allowed to reach room temperature before use.
2	Add 25 ul of Biotinylated CCP Peptide in appropriate wells.
3	Add 100 ul Standard, High Control, Low Control and Diluted Sample in appropriate wells in duplicate.
4	Cover the plate and incubate for 60 minutes at room temperature (22-28°C).
5	Aspirate and wash plate 5 times with (1x) Wash Buffer and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe of any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step. All the washes should be performed similarly.
6	Add 100 ul of Anti-Human IgG:HRP Conjugate to each well.
7	Cover the plate and incubate for 30 minutes at room temperature (22-28°C).
8	Repeat the Wash Step as mentioned in step 5.
9	Add 100 ul of TMB Substrate into each well.
10	Incubate for 15 minutes at room temperature (22-28°C).
11	Add 100 ul of Stop Solution . Read result with an ELISA reader at 450 nm within 15 minutes stopping the reaction.

SYMBOLS KEY

MTP	Microtiter Plate (96 wells)
STD	Standards
SAMP DIL	Sample Diluent
LC	Low Control Serum
HC	High Control Serum
BIOTIN CCP	Biotinylated CCP Peptide
20X HRP CONJ	Anti-Human-IgG:HRP Conjugate
HRP DIL	HRP Conjugate Diluent
10X WASH BUF	(10X) Wash Buffer
SUB TMB	TMB Substrate
SOLN STOP	Stop Solution
	Consult Instructions for Use
REF	Catalog Number
	Expiration Date
	Storage Temperature